Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 200 publications.
Skip to main content
Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster presented at the ISPOR 2025; May 16, 2025. Montréal, Canada.
La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N. Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster presented at the ISPOR 2025; May 13, 2025. Montréal, Canada.
Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Modeled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years at increased risk for severe RSV disease in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.
Verelst F, La E, Singer D, Graham J, Grace M, Biundo E, Poston S. Modelled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 60 years and older in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.
Carrico J, Talbird SE, Eiden A, Carias C, Huang M, Lang JC, Marshall GS, Bencina G. Direct impact of pediatric immunization on reduction in antibiotic prescribing in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.
Anderson SA, Bian B, Talbird SE, Stratton M, Maxwell R, Ferries R. Medical cost and healthcare resource utilization offset for zuranolone relative to SSRIs in the treatment of postpartum depression. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.
Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. Public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of CMV and congenital CMV in the United States. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, The Netherlands. Previously presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024.
Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. The public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 24, 2024. Copenhagen, Germany.
Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Real-world impact of pneumococcal conjugate vaccines on invasive pneumococcal disease for serotypes missing prespecified efficacy threshold in immunogenicity trials. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Shah HA, Herrera-Restrepo O, Jutlla G, Grace M, Graham J, Khan SA, Begum S, Kocaata K. Market and non-market productivity losses associated with invasive meningococcal disease (IMD) in the United States (US). Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Shah HA, Herrera-Restrepo O, Jutlla G, Carrico J, Hicks K, Kuylen E, Begum S, Clements D, Burman C, Sohn WY, Kocaata Z. Public health impact of MENABCWY vaccination in adolescents and MENB vaccination in infants in the United States. Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Golan Y, Amin AN, Wilson M, Nguyen D, Kvasz M. Clinical and economic outcomes of microbiome therapy for preventing recurrence in recurrent clostridioides difficile infection (Cdi) in the us: comparison of fecal microbiota spores, live-brpk (formerly Ser-109) Vs fecal microbiota, live-Jslm. Poster presented at the Digestive Disease Week (DDW) 2024; May 18, 2024. Washington, DC.
La E, Singer D, Graham J, Grace M, Molnar D. Modeled public health impact of increasing respiratory syncytial virus vaccination coverage among adults Aged ≥ 60 years in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024.
Hohmann C, Manga N, Wolowacz S, Bregantini D, Pfister R. Impact of bempedoic acid on CV outcomes and costs in Germany. Poster presented at the 130th Congress of the German Society of Internal Medicine; April 13, 2024. Wiesbaden, Germany.
La E, Verelst F, Curran D, Poston S, Graham J, Molnar D. Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults AGED ≥60 years in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled burden of RSV in adults aged 50-59 years with chronic cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled impact of adjuvanted RSVPREF3 vaccination on RSV-related health outcomes in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
Morris MJ, Armstrong AJ, Chi K, de Bono J, Herrmann K, Krause B, Rahbar K, Sartor O, Tagawa ST, Nagarajah J, Wei XX, Nordquist LT, Koshkin VS, Saad F, Vickers A, Ghouse R, Wu J, Mirante O, Fizazi K. Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer. Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.
Ghaswalla P, Hitchens A, Candrilli SD, Carrico J, Hicks KA, Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018. Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.
Knight C, Lin YC, Pelaez SM, Aragon JR. Cost analysis of Nuvaxovid™ COVID-19 vaccine as an annual booster dose for COVID-19 prevention in people older than 60 years in Spain. Poster presented at the XXII National Congress - XI International: Preventive medicine in society: a challenge for the future; September 20, 2023. Palma De Mallorca, Spain.
Razavi M, Herring WL, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of transitions to later stages of Alzheimer's disease in Europe: elevating the sense of urgency to treat. Poster presented at the AAIC 2023 Conference; July 16, 2023. Amsterdam, Netherlands.
Davis A, Cook C, Graham J, Diaz-Decaro J, Myers E, Buck P. Modelling the public health impact of routine pediatric vaccination for the prevention of cytomegalovirus and congenital cytomegalovirus at the population-level. Poster presented at the 41st Annual Meeting of ESPID 2023; May 8, 2023. Lisbon, Portugal.
George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2023 Canadian Immunization Conference; April 25, 2023. Ottawa, Canada. Previously presented at the 2022 Canadian Association for Population Therapeutics Conference.
Molnar D, La E, Verelst F, Curran D, Poston S, Graham J. Modeling the clinical and economic burden of respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Talbird S, Cook C, DeMartino J, Hernandez-Pastor L, Krishnarajah G. Projected impact of RSV vaccine in US adults ≥ 60 years of age. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Razavi M, Herring W, Gillis C, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of daily transitions to later stages of AD dementia in the US. Poster presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD); December 2, 2022. San Francisco, CA.
Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782
Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Population-level model of the health and economic impact of NVX-CoV2373 as a COVID-19 booster vaccine option for adults in the United States. Poster presented at the Society for Medical Decision Making (SMDM) 44th Annual North American Meeting; October 25, 2022. Seattle, WA.
George S, Carrico J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged 50 years and older. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.
George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.
Bell T, Fernandez M, Khan S, Tumminello B, Bektas M, Heyes CE, Oton AB. Patient burden of illness associated with desmoid tumors. Poster presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting; September 24, 2022. Philadelphia, PA.
Ray KK, Catapano AL, Diamand F, Wolowacz S, Haq I, Bilitou A. Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients. Poster presented at the European Society of Cardiology Congress 2022; August 26, 2022. Barcelona, Spain.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Estimating the historical population-level impact of PCV13 national immunization programs on invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Non-vaccine serotype population-level trends for invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Sundaram V, Wasserman M, Palmborg A, McDade C, Dorange AC, Wilson M, Perdrizet J. Comparing the public health impact of the pediatric 15- and 20-valent pneumococcal conjugate vaccine in Sweden. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.
Sundaram V, Perdrizet J, Wasserman M, Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A. Comparing the public health impact of switching to pediatric 13-valent pneumococcal conjugate vaccine in the near-term and higher-valent pneumococcal conjugate vaccines in the long-term in the Netherlands. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.
Mikudina B, Vyse AJ, Czudek C, Ellsbury GF, Perdrizet J, Wasserman M, McDade C, Wilson M. Infant pneumococcal conjugate vaccine programs result in substantial cost-savings and cases averted in the United Kingdom. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.
Teixeira R, da Silva Maia AS, Sundaram V, Wasserman M, Horn EK, McDade C, Wilson M, Perdizet J. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine paediatric national immunisation programme in Portugal. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.
Curran D, Patterson BJ, Carrico J, Salem AE, La EM, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the IDWeek 2021 Virtual Conference; September 29, 2021.
Davis A, Jiang J, Talbird S, Turpin RS, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual Digestive Disease Week (DDW) Conference; May 21, 2021. Previously presented at the 2021 AMCP Conference.
Gandola AE, Ait Sarkouh R, Orfanos P, Bouisset F, Licitra L, Bourhis J, Mladsi D, Chirila C, Paret K, Barnett C. An early cost-effectiveness analysis of xevinapant in combination with chemo-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck in United States. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.
Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Poster presented at the 2021 Virtual AMCP; April 12, 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting.